Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Merck Sharp & Dohme LLC
Sotio Biotech Inc.
PMV Pharmaceuticals, Inc
NeoImmuneTech
Neonc Technologies, Inc.
ImmunityBio, Inc.
VM Oncology, LLC
Amgen
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
OncoC4, Inc.
Inspirna, Inc.
Seagen Inc.
Carisma Therapeutics Inc
Sellas Life Sciences Group
Salubris Biotherapeutics Inc
Evopoint Biosciences Inc.
Fate Therapeutics
Xencor, Inc.
Merck Sharp & Dohme LLC
Gossamer Bio Inc.
Aeglea Biotherapeutics
Incyte Corporation
Merck Sharp & Dohme LLC
MultiVir, Inc.
Incyte Corporation